Sporaxol (itraconazole) capsules 100 mg. №10.


Vulvovaginal candidiasis; seeding lichen; dermatomycosis caused by itraconazole-sensitive pathogens (Trichophyton spp., Microsporum spp., Epidermophyton floccosum), such as foot dermatophytosis, inguinal dermatomycosis, trunk dermatophytosis, hand dermatophytosis; oropharyngeal candidiasis; onychomycosis caused by dermatophytes and / or yeast; histoplasmosis; systemic mycoses (in cases where first-line antifungal therapy cannot be applied, or in case of ineffectiveness of treatment with other antifungal drugs, which may be due to pathology, pathogen insensitivity or toxicity of the drug): aspergillosis and candidiasis; cryptococcosis (including cryptococcal meningitis): treatment of immunocompromised patients with cryptococcosis and all patients with cryptococcosis of the central nervous system; supportive therapy in patients with AIDS to prevent recurrence of existing fungal infection. Itraconazole is also prescribed for the prevention of fungal infection in patients with prolonged neutropenia in cases where standard therapy is insufficient.



Composition and form of release
The main active drug of the drug is itraconazole. Excipients – spherical sugar, hypromellose, titanium dioxide, etc.
Available in capsule form at a dosage of 100 mg.
Pharmacological properties
A synthetic antifungal drug intended for systemic use. The active agent of the drug is itraconazole.
The mechanism of action is due to its ability to inhibit the synthesis of ergosterol, which is an important component of the fungal cell membrane.
It is prescribed for the treatment of mycoses caused by pathogens that are sensitive to this drug, including diseases such as:

  • vulvovaginal candidomycosis;
  • chronic recurrent fungal vulvovaginitis;
  • mycoses of the skin, oral cavity, eyes, onychomycosis caused by dermatophytes or yeasts;
  • aspergillosis of the lungs and extrapulmonary localization in patients suffering from intolerance or refraction to amphotericin B therapy;
  • systemic mycoses, including systemic aspergillosis, candidiasis, cryptococcosis, including cryptococcal meningitis;
  • histoplasmosis (including chronic pulmonary, disseminated, not meningeal), sporotrichosis, paracoccidioidosis, blastomycosis, as well as other systemic, including rare and tropical mycoses.

Trichophyton spp., Epidermophyton floccosum, Microsporum spp., Candida spp. Are sensitive to itraconazole. (including C. albicans), Cryptococcus noeformans, Sporothix schencki, Fonsecaea spp., Cladosporium spp., Blastomyces dermatidis, some other microorganisms.
Contraindicated in case of allergy to itraconazole, or other active ingredient of the drug.
It is contraindicated to use with CYP3A4 substrates, eletriptan, nizoldipine, simvastatin, lovastatin, triazolam, midazolam. Also, it should not be used in patients with ventricular dysfunction.
The encapsulated form is not recommended for children under 15 years of age.
Application during pregnancy and lactation
Application during pregnancy and lactation is possible only when the tangible positive effects for the body are higher than the likely harm caused.
Breastfeeding is stopped during treatment with itraconazole.
Method of administration and dosage
Sporaxol is taken immediately after meals, 1-2 times a day. The exact dosage and course of treatment is prescribed by the attending physician. Usually prescribed for treatment:

  • vulvovaginal candidiasis – 1 day – 200 mg, 2 times a day or 3 days, 200 mg 1 time a day.
  • chronic recurrent fungal vulvovaginitis – 100 mg 2 times a day (1 week), and during the next 3-6 menstrual cycles, take 100 mg on the first day of the cycle.
  • lichen – 200 mg once a day (1 week);
  • dermatomycosis – 100 mg once a day (15 days), with lesions of the skin of the hands or feet – additionally the same dose is taken for another 15 days;
  • oral candidiasis – 100 mg, once a day (15 days);
  • fungal keratitis – 200 mg, 1 time per day (3 weeks);
  • onychomycosis – 200 mg once a day (3 months), with damage to the nails on the toes – 3 courses, taking 1 week and 3 weeks off, on the hands – 2 such courses;
  • systemic candidiasis – 100-200 mg, 1 time per day (from 3 weeks to 7 months), the dose may be doubled;
  • systemic cryptococcosis without meningitis – 200 mg once a day, with meningitis – 2 times a day.
  • Maintenance therapy – once a day (2-12 months);
  • histoplasmosis – 200 mg, 1-2 times a day, (6-8 months);
  • sporotrichosis – 100 mg, once a day (6 months);
  • chromomycosis – 100-200 mg, once a day (6 months);
  • aspergillosis – 200 mg 1-2 times a day (2-5 months);
  • blastomycosis – 100-200 mg 1-2 times a day (6 months).

With weakened immunity, dosages may be increased.
To date, no cases of overdose have been recorded. If an overdose occurs, you should rinse the stomach, take sorbents.
Side effects
The most common side effects are:

  • dyspepsia, nausea, constipation, hepatitis;
  • headache, dizziness, peripheral neuropathy;
  • allergic reactions such as pruritus, urticaria, angioedema;
  • dysmenorrhea, hypokalemia (rarely).

Storage conditions and periods
The shelf life of capsules is up to 2 years. Stored at a temperature not exceeding 25 ° C.